This grant by HHS/CDC aims to provide technical assistance and capacity building to PEPFAR and Global Fund-supported activities in Mozambique for HIV/AIDS services. It will focus on critical areas such as PMTCT, clinical services, surveillance, and laboratory support. With a high HIV prevalence of 11.5% nationally, the program seeks to improve testing rates and access to care for the estimated 1,655,167 PLHIV in the country. The goal is to implement evidence-based interventions for HIV and TB control, including addressing key populations’ needs and strengthening healthcare systems. Awardees will be expected to support the government and stakeholders in achieving epidemic control through sustainable service models.
Opportunity ID: 316160
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-GH16-16320301SUPP19 |
| Funding Opportunity Title: | Supporting Implementation of HIV and TB Services for Epidemic Control in the Republic of Mozambique under PEPFAR |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | Supplement |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.067 — Global AIDS |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 20, 2019 |
| Last Updated Date: | May 20, 2019 |
| Original Closing Date for Applications: | Jul 01, 2019 Electronically submitted applications must be submitted no later than 11:59 p.m., ET, on the listed application due date. |
| Current Closing Date for Applications: | Jul 01, 2019 Electronically submitted applications must be submitted no later than 11:59 p.m., ET, on the listed application due date. |
| Archive Date: | Jul 31, 2019 |
| Estimated Total Program Funding: | $1,037,398 |
| Award Ceiling: | $1,037,398 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Based on UNAIDS report released in Dec 2014, the global HIV/AIDS epidemic has reached a turning point and unless immediate actions are taken, the HIV/AIDS epidemic will become unmanageable by 2020. In an effort to turn the tide against HIV/AIDS epidemic in Mozambique, USG has identified a core set of evidence-based interventions that needs to be implemented and brought to scale rapidly. HIV/AIDS is the leading cause of death for adults and the second leading cause of death for children in Mozambique. HIV/AIDS leads to more than 44,000 deaths and more than 88,000 new infections annually in Mozambique. Due to the worsening situation in Mozambique, USG has committed to rapidly scaling up evidence-based interventions in identified ‘hot spots’ throughout the country.CDC is the largest USG agency providing HIV clinical services in Mozambique and has the largest reach of any USG agency to quickly expand HIV services to curb the growing HIV trend. AGPAHI, CDC Mozambique’s lead partner for implementing evidence-based HIV Care and Treatment activities in Maputo province, more specifically Matola District where HIV index-case data suggests that CDC Mozambique must act immediately to contributes towards epidemic control. The Mozambique Ministry of Health (MOH) is the national public health agency that designs health policies, provides leadership and oversight to the national HIV response in the Republic of Mozambique. CDC partners operate within public health facilities managed by the MOH.The MOH has agreed to a specific geographical distribution of CDC partners in order to ensure coordination, reduce duplication of efforts and maximize the impact of partners implementing the PEPFAR program throughout the country. Partners are not permitted to operate outside of this agreed upon distribution or in a health facility already operated by another partner. Based on this distribution, AGPAHI is the only partner that can carry out Matola Surge activities in the city of Matola. |
Additional Information
| Agency Name: | Centers for Disease Control – CGH |
| Description: | The goal and objectives of the program is to solicit comprehensive and cost-effective technical assistance, capacity building and program implementation expertise for PEPFAR and Global Fund-supported global health activities (with emphasis on but not limited to HIV/AIDS) in the five programmatic areas listed under the purpose section of this FOA. This announcement will also support Global Fund implementing partners in assessing HIV service delivery and will develop technical assistance plans and strategies. This FOA will not provide direct program implementation. Rather, it will provide technical assistance support to PEPFAR and Global Fund implementing partners engaged in program implementation and scale-up activities.This FOA will support HHS/CDC’s efforts to provide high-quality, targeted technical assistance to ensure that the PEPFAR and Global Fund-supported countries have the capacity and necessary technical expertise to assume responsibility for service delivery and adequately respond to their HIV epidemics. While this announcement will address several of the overall program goals and objectives, it will primarily focus on five critical PEPFAR-supported technical areas. Applicants are expected to respond to one or more of the following program areas:Prevention of Mother-to-Child Transmission of HIV/AIDS (PMTCT);HIV Care and Treatment Clinical Services for adults and children;HIV Pediatric Care and Treatment (PEDs);Surveillance and Strategic Information (SI); andLaboratoryMozambique is a predominantly rural country with a population of 26 million people. The 2009 National AIDS Survey (INSIDA), the latest nationally- and provincially-representative population-based survey for which representative results are available, showed the national HIV prevalence to be 11.5%; although there was substantial variation in regional HIV prevalence, ranging from 25.1% in Southern provinces to 3.7% in Northern provinces. Generally, HIV testing in Mozambique has remained low; INSIDA 2009 found that only 37% of women and 19% of men aged 15-49 had ever been tested for HIV. As per official UNAIDS estimates, in 2014, an estimated 1,655,167 people were living with HIV (PLHIV), with a higher prevalence among women (13.1% vs 9.2% in men) and especially among young women aged 15-24 years (estimated HIV prevalence is 11.1% vs 3.1% in young men). The HIV epidemic has contributed to a low life expectancy of 51 years, and there are about 848,000 orphaned children. As of 2014, approximately 54% of estimated PLHIV were in care and 40% were on antiretroviral therapy (ART). TB is a public health concern in the country, with TB case detection rates and TB/HIV co-infection rates of 37% and 56%, respectively.While epidemiological data on key populations (KP) in Mozambique is limited, integrated biological and behavioral surveillance (IBBS) 2011/2012 data indicated that the prevalence of HIV among female sex workers was 31.2% in Maputo, 23.6% in Beira, and 17.8% in Nampula.The overall goal of this NOFO is to implement interventions to support the continuum of response for HIV and TB in Mozambique. As such, awardees will be expected to implement comprehensive and evidence-based interventions to support prevention, care, support, and treatment interventions for HIV and TB in facilities and communities. This also includes, but is not limited to the following cross-cutting areas that are critical for achieving epidemic control: HRH, GBV, HSS, laboratory, surveillance and surveys, sexual prevention, health communication, health economics, performance-based financing, epidemiologic assistance, DQA, monitoring and evaluation (M&E), information systems, and impact and program evaluation.Awardees will also be expected to provide technical assistance and capacity building support to host governmental institutions and other stakeholders/partners, including GF recipients, involved in providing HIV and TB services in Mozambique.The purpose of this NOFO is to support the Government of Mozambique to achieve epidemic control through delivery of high quality HIV anThe purpose of this NOFO is to support the Government of Mozambique to achieve epidemic control through delivery of high quality HIV and TB services by implementing sustainable models of community and facility based services that cover the full continuum of response. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
OGSTIMS@cdc.gov
770-488-2700 Email:ogstims@cdc.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Supplement | May 20, 2019 | |
| May 20, 2019 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-GH16-16320301SUPP19 |
| Funding Opportunity Title: | Supporting Implementation of HIV and TB Services for Epidemic Control in the Republic of Mozambique under PEPFAR |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | Supplement |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.067 — Global AIDS |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 20, 2019 |
| Last Updated Date: | May 20, 2019 |
| Original Closing Date for Applications: | Jul 01, 2019 Electronically submitted applications must be submitted no later than 11:59 p.m., ET, on the listed application due date. |
| Current Closing Date for Applications: | Jul 01, 2019 Electronically submitted applications must be submitted no later than 11:59 p.m., ET, on the listed application due date. |
| Archive Date: | Jul 31, 2019 |
| Estimated Total Program Funding: | $1,037,398 |
| Award Ceiling: | $1,037,398 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Based on UNAIDS report released in Dec 2014, the global HIV/AIDS epidemic has reached a turning point and unless immediate actions are taken, the HIV/AIDS epidemic will become unmanageable by 2020. In an effort to turn the tide against HIV/AIDS epidemic in Mozambique, USG has identified a core set of evidence-based interventions that needs to be implemented and brought to scale rapidly. HIV/AIDS is the leading cause of death for adults and the second leading cause of death for children in Mozambique. HIV/AIDS leads to more than 44,000 deaths and more than 88,000 new infections annually in Mozambique. Due to the worsening situation in Mozambique, USG has committed to rapidly scaling up evidence-based interventions in identified ‘hot spots’ throughout the country.CDC is the largest USG agency providing HIV clinical services in Mozambique and has the largest reach of any USG agency to quickly expand HIV services to curb the growing HIV trend. AGPAHI, CDC Mozambique’s lead partner for implementing evidence-based HIV Care and Treatment activities in Maputo province, more specifically Matola District where HIV index-case data suggests that CDC Mozambique must act immediately to contributes towards epidemic control. The Mozambique Ministry of Health (MOH) is the national public health agency that designs health policies, provides leadership and oversight to the national HIV response in the Republic of Mozambique. CDC partners operate within public health facilities managed by the MOH.The MOH has agreed to a specific geographical distribution of CDC partners in order to ensure coordination, reduce duplication of efforts and maximize the impact of partners implementing the PEPFAR program throughout the country. Partners are not permitted to operate outside of this agreed upon distribution or in a health facility already operated by another partner. Based on this distribution, AGPAHI is the only partner that can carry out Matola Surge activities in the city of Matola. |
Additional Information
| Agency Name: | Centers for Disease Control – CGH |
| Description: | The goal and objectives of the program is to solicit comprehensive and cost-effective technical assistance, capacity building and program implementation expertise for PEPFAR and Global Fund-supported global health activities (with emphasis on but not limited to HIV/AIDS) in the five programmatic areas listed under the purpose section of this FOA. This announcement will also support Global Fund implementing partners in assessing HIV service delivery and will develop technical assistance plans and strategies. This FOA will not provide direct program implementation. Rather, it will provide technical assistance support to PEPFAR and Global Fund implementing partners engaged in program implementation and scale-up activities.This FOA will support HHS/CDC’s efforts to provide high-quality, targeted technical assistance to ensure that the PEPFAR and Global Fund-supported countries have the capacity and necessary technical expertise to assume responsibility for service delivery and adequately respond to their HIV epidemics. While this announcement will address several of the overall program goals and objectives, it will primarily focus on five critical PEPFAR-supported technical areas. Applicants are expected to respond to one or more of the following program areas:Prevention of Mother-to-Child Transmission of HIV/AIDS (PMTCT);HIV Care and Treatment Clinical Services for adults and children;HIV Pediatric Care and Treatment (PEDs);Surveillance and Strategic Information (SI); andLaboratoryMozambique is a predominantly rural country with a population of 26 million people. The 2009 National AIDS Survey (INSIDA), the latest nationally- and provincially-representative population-based survey for which representative results are available, showed the national HIV prevalence to be 11.5%; although there was substantial variation in regional HIV prevalence, ranging from 25.1% in Southern provinces to 3.7% in Northern provinces. Generally, HIV testing in Mozambique has remained low; INSIDA 2009 found that only 37% of women and 19% of men aged 15-49 had ever been tested for HIV. As per official UNAIDS estimates, in 2014, an estimated 1,655,167 people were living with HIV (PLHIV), with a higher prevalence among women (13.1% vs 9.2% in men) and especially among young women aged 15-24 years (estimated HIV prevalence is 11.1% vs 3.1% in young men). The HIV epidemic has contributed to a low life expectancy of 51 years, and there are about 848,000 orphaned children. As of 2014, approximately 54% of estimated PLHIV were in care and 40% were on antiretroviral therapy (ART). TB is a public health concern in the country, with TB case detection rates and TB/HIV co-infection rates of 37% and 56%, respectively.While epidemiological data on key populations (KP) in Mozambique is limited, integrated biological and behavioral surveillance (IBBS) 2011/2012 data indicated that the prevalence of HIV among female sex workers was 31.2% in Maputo, 23.6% in Beira, and 17.8% in Nampula.The overall goal of this NOFO is to implement interventions to support the continuum of response for HIV and TB in Mozambique. As such, awardees will be expected to implement comprehensive and evidence-based interventions to support prevention, care, support, and treatment interventions for HIV and TB in facilities and communities. This also includes, but is not limited to the following cross-cutting areas that are critical for achieving epidemic control: HRH, GBV, HSS, laboratory, surveillance and surveys, sexual prevention, health communication, health economics, performance-based financing, epidemiologic assistance, DQA, monitoring and evaluation (M&E), information systems, and impact and program evaluation.Awardees will also be expected to provide technical assistance and capacity building support to host governmental institutions and other stakeholders/partners, including GF recipients, involved in providing HIV and TB services in Mozambique.The purpose of this NOFO is to support the Government of Mozambique to achieve epidemic control through delivery of high quality HIV anThe purpose of this NOFO is to support the Government of Mozambique to achieve epidemic control through delivery of high quality HIV and TB services by implementing sustainable models of community and facility based services that cover the full continuum of response. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
OGSTIMS@cdc.gov
770-488-2700 Email:ogstims@cdc.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-GH16-16320301SUPP19 |
| Funding Opportunity Title: | Supporting Implementation of HIV and TB Services for Epidemic Control in the Republic of Mozambique under PEPFAR |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.067 — Global AIDS |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 20, 2019 |
| Last Updated Date: | May 20, 2019 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jul 01, 2019 Electronically submitted applications must be submitted no later than 11:59 p.m., ET, on the listed application due date. |
| Archive Date: | Jul 31, 2019 |
| Estimated Total Program Funding: | $1,037,398 |
| Award Ceiling: | $1,037,398 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Based on UNAIDS report released in Dec 2014, the global HIV/AIDS epidemic has reached a turning point and unless immediate actions are taken, the HIV/AIDS epidemic will become unmanageable by 2020. In an effort to turn the tide against HIV/AIDS epidemic in Mozambique, USG has identified a core set of evidence-based interventions that needs to be implemented and brought to scale rapidly. HIV/AIDS is the leading cause of death for adults and the second leading cause of death for children in Mozambique. HIV/AIDS leads to more than 44,000 deaths and more than 88,000 new infections annually in Mozambique. Due to the worsening situation in Mozambique, USG has committed to rapidly scaling up evidence-based interventions in identified ‘hot spots’ throughout the country. CDC is the largest USG agency providing HIV clinical services in Mozambique and has the largest reach of any USG agency to quickly expand HIV services to curb the growing HIV trend. AGPAHI, CDC Mozambique’s lead partner for implementing evidence-based HIV Care and Treatment activities in Maputo province, more specifically Matola District where HIV index-case data suggests that CDC Mozambique must act immediately to contributes towards epidemic control. The Mozambique Ministry of Health (MOH) is the national public health agency that designs health policies, provides leadership and oversight to the national HIV response in the Republic of Mozambique. CDC partners operate within public health facilities managed by the MOH. The MOH has agreed to a specific geographical distribution of CDC partners in order to ensure coordination, reduce duplication of efforts and maximize the impact of partners implementing the PEPFAR program throughout the country. Partners are not permitted to operate outside of this agreed upon distribution or in a health facility already operated by another partner. Based on this distribution, AGPAHI is the only partner that can carry out Matola Surge activities in the city of Matola. |
Additional Information
| Agency Name: | Centers for Disease Control – CGH |
| Description: | The goal and objectives of the program is to solicit comprehensive and cost-effective technical assistance, capacity building and program implementation expertise for PEPFAR and Global Fund-supported global health activities (with emphasis on but not limited to HIV/AIDS) in the five programmatic areas listed under the purpose section of this FOA. This announcement will also support Global Fund implementing partners in assessing HIV service delivery and will develop technical assistance plans and strategies. This FOA will not provide direct program implementation. Rather, it will provide technical assistance support to PEPFAR and Global Fund implementing partners engaged in program implementation and scale-up activities. This FOA will support HHS/CDC’s efforts to provide high-quality, targeted technical assistance to ensure that the PEPFAR and Global Fund-supported countries have the capacity and necessary technical expertise to assume responsibility for service delivery and adequately respond to their HIV epidemics. While this announcement will address several of the overall program goals and objectives, it will primarily focus on five critical PEPFAR-supported technical areas. Applicants are expected to respond to one or more of the following program areas: Prevention of Mother-to-Child Transmission of HIV/AIDS (PMTCT); Mozambique is a predominantly rural country with a population of 26 million people. The 2009 National AIDS Survey (INSIDA), the latest nationally- and provincially-representative population-based survey for which representative results are available, showed the national HIV prevalence to be 11.5%; although there was substantial variation in regional HIV prevalence, ranging from 25.1% in Southern provinces to 3.7% in Northern provinces. Generally, HIV testing in Mozambique has remained low; INSIDA 2009 found that only 37% of women and 19% of men aged 15-49 had ever been tested for HIV. As per official UNAIDS estimates, in 2014, an estimated 1,655,167 people were living with HIV (PLHIV), with a higher prevalence among women (13.1% vs 9.2% in men) and especially among young women aged 15-24 years (estimated HIV prevalence is 11.1% vs 3.1% in young men). The HIV epidemic has contributed to a low life expectancy of 51 years, and there are about 848,000 orphaned children. As of 2014, approximately 54% of estimated PLHIV were in care and 40% were on antiretroviral therapy (ART). TB is a public health concern in the country, with TB case detection rates and TB/HIV co-infection rates of 37% and 56%, respectively. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Emily Dale
dln6@cdc.gov Email:dln6@cdc.gov |
Related Documents
Folder 316160 Full Announcement-FULL_ANNOUNCEMENT -> NOFO GH16-16320301SUPP19.pdf
Packages
| Agency Contact Information: | OGSTIMS@cdc.gov 770-488-2700 Email: ogstims@cdc.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.067 | CDC-RFA-GH16-16320301SUPP19 | Supporting Implementation of HIV and TB Services for Epidemic Control in the Republic of Mozambique under PEPFAR | PKG00251122 | May 20, 2019 | Jul 01, 2019 | View |
Package 1
Mandatory forms
316160 SF424_2_1-2.1.pdf
316160 SFLLL_1_2-1.2.pdf
316160 SF424A-1.0.pdf
316160 HHS_CheckList_2_1-2.1.pdf
316160 ProjectNarrativeAttachments_1_2-1.2.pdf
316160 BudgetNarrativeAttachments_1_2-1.2.pdf
Optional forms
316160 OtherNarrativeAttachments_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
